Patents Assigned to The Broad Institute
  • Patent number: 10064853
    Abstract: The invention provides compounds of formula (I) that inhibit PDI, for use in methods to treat or prevent a disease or condition in a subject that would benefit by inhibition of PDI.
    Type: Grant
    Filed: June 26, 2017
    Date of Patent: September 4, 2018
    Assignees: Beth Israel Deaconess Medical Center, Inc., The Broad Institute, Inc.
    Inventors: Robert Flaumenhaft, Partha Pratim Nag, Tatiana Pilyugina, Jun Pu, Sivaraman Dandapani, Benito Munoz, Chris Dockendorff
  • Patent number: 10065989
    Abstract: The present invention relates to compositions which may comprise a molecular sled linked to cargo and uses thereof. In particular, the present invention relates to a non-naturally occurring or engineered composition which may comprise a molecular sled, linkers and a molecular cargo connected to the sled via the linkers. Methods involving the use of molecular sleds and their cargoes and pharmaceutical compositions, methods for treating cancer, a degenerative disease, a genetic disease or an infectious disease as well as diagnostic methods are also contemplated by the present invention.
    Type: Grant
    Filed: January 13, 2015
    Date of Patent: September 4, 2018
    Assignees: The Broad Institute Inc., President and Fellows of Harvard College, Rijksuniversiteit Groningen
    Inventors: Walter F. Mangel, Paul Blainey, Vito Graziano, Andreas Herrmann, William J. McGrath, Antonius Martinus Van Oijen, Xiaoliang Sunney Xie
  • Patent number: 10059711
    Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of malaria.
    Type: Grant
    Filed: November 11, 2014
    Date of Patent: August 28, 2018
    Assignee: The Broad Institute, Inc.
    Inventors: Eamon Comer, Nobutaka Kato, Christina Scherer, Jessica Bastien, Jeremy Duvall, Timothy Lewis, Morgane Sayes, Matthew Leighty, Jun Pu, Jennifer Beaudoin, Bertrand Braibant, Benito Munoz
  • Publication number: 20180235961
    Abstract: The present invention features improved methods of identifying patients having cancer (e.g., melanoma, adenocarcinoma, lung, cervical, liver or breast cancer) using biomarkers (e.g., PDE3A, SLFN12) that correlate with drug sensitivity and consequently treating a stratified patient population with an agent of the invention (e.g., DNMDP, zardaverine, and anagrelide).
    Type: Application
    Filed: August 12, 2016
    Publication date: August 23, 2018
    Applicants: The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc., Bayer Pharma AG
    Inventors: Luc De Waal, Matthew Meyerson, Heidi Greulich, Monica Schenone, Alex Burgin, Xiaoyun Wu, Ulrike Sack
  • Publication number: 20180221379
    Abstract: The present disclosure provides methods of treating and/or preventing inflammatory bowel disease (IBD) and graft-versus-host disease (GVHD) using salt-inducible kinase (SIK) inhibitors, such as macrocyclic SIK inhibitors of Formula (I), imidazolyl SIK inhibitors of Formula (II), and urea and carbamate SIK inhibitors of Formula (III-A) (e.g., urea and carbamate SIK inhibitors of Formula (III)).
    Type: Application
    Filed: December 19, 2017
    Publication date: August 9, 2018
    Applicants: Dana-Farber Cancer Institute, Inc., The Broad Institute, Inc., President and Fellows of Harvard College, The General Hospital Corporation d/b/a Massachusetts General Hospital
    Inventors: Alykhan Shamji, Thomas Sundberg, Nathanael Gray, Ramnik Xavier, Stuart L. Schreiber, Hwan Geun Choi, Yanke Liang
  • Publication number: 20180215726
    Abstract: The present invention provides compounds of formula (I): or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein W, X, n, s, t, and Ra are as described herein. The present invention relates generally to selective inhibitors of histone deacetylase and to methods of making and using them.
    Type: Application
    Filed: January 24, 2018
    Publication date: August 2, 2018
    Applicant: The Broad Institute, Inc.
    Inventors: Edward Holson, Fanny Lazzaro, David Olson, Florence Fevrier Wagner, Michel Weiwer
  • Patent number: 10024860
    Abstract: Proteomic methods for identifying cancer related proteins and related products and kits are provided. The cancer specific proteins are extracellular matrix proteins that are associated with various aspects of cancer. Panels or signature sets of proteins useful in the detection, diagnosis and treatment of cancers as well as monitoring therapeutic progress in a cancer patient are provided herein along with methods for their detection and for their use in targeting imaging and/or therapeutic agents to the tumors via binding to the specified proteins. The proteins were identified using proteomics analyzes of tissue samples taken from cancer patients. In certain aspects the proteins are particularly useful in colon cancer patients.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: July 17, 2018
    Assignees: Massachusetts Institute of Technology, The General Hospital Corporation, The Broad Institute, Inc.
    Inventors: Richard O. Hynes, Alexandra Naba, Karl Clauser, Steven A. Carr, Kenneth Tanabe
  • Publication number: 20180171297
    Abstract: Provided herein are nucleic acid molecules that target the BCL11A enhancer functional regions, compositions comprising the nucleic acid molecules and methods for increasing fetal hemoglobin levels in a cell by disrupting BCL11A expression at the genomic level. Also provided herein are methods and compositions relating to the treatment of hemoglobinopathies by reinduction of fetal hemoglobin levels. In particular, the nucleic acid molecules target the +62, +58, and/or the +55 enhancer functional regions.
    Type: Application
    Filed: May 6, 2016
    Publication date: June 21, 2018
    Applicants: The Children's Medical Center Corporation, The Broad Institute, Inc., Massachusetts Institute of Technology
    Inventors: Daniel E. Bauer, Stuart H. Orkin, Neville Sanjana, Ophir Shalem, Feng Zhang
  • Publication number: 20180155283
    Abstract: The present invention relates to novel dopamine D2 receptor ligands. The invention further relates to functionally-biased dopamine D2 receptor ligands and the use of these compounds for treating or preventing central nervous system and systemic disorders associated with dysregulation of dopammode inergic activity. The present invention relates to novel compounds that modulate dopamine D2 receptors. In particular, compounds of the present invention show functional selectivity at the dopamine D2 receptors and exhibit selectivity downstream of the D2 receptors, on the 0-arrestin pathway and/or on the cAMP pathway.
    Type: Application
    Filed: December 18, 2015
    Publication date: June 7, 2018
    Applicants: The Broad Institute, Inc., Massachusetts Institute of Technology
    Inventors: Edward Holson, Florence Fevrier Wagner, Michel Weiwer, Edward Scolnick, Michelle Palmer, Luka Dordevic, Michael C. Lewis, Jennifer Q. Pan, Yan-Ling Zhang, Qihong Xu
  • Patent number: 9974289
    Abstract: The present invention features a knock-in mouse comprising a mutation in an endogenous CRBN locus and methods of use thereof.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: May 22, 2018
    Assignees: The Broad Institute, Inc., The Brigham and Women's Hospital, Inc.
    Inventors: Benjamin Levine Ebert, Jan Krönke, Steven A. Carr, Namrata D. Udeshi, Emma Fink
  • Patent number: 9951055
    Abstract: This application describes compounds and methods that can inhibit Scavenger receptor class B, type I (SR-BI) activity, which compounds and methods can used, for example, to mediate high-density lipoprotein (HDL) lipid uptake and treat hepatitis C viral infections.
    Type: Grant
    Filed: October 21, 2013
    Date of Patent: April 24, 2018
    Assignees: Massachusetts Institute of Technology, The Broad Institute, Inc.
    Inventors: Chris Dockendorff, Willmen Youngsaye, Partha Pratim Nag, Timothy A. Lewis, Sivaraman Dandapani, Benito Munoz, Patrick Faloon, Thomas Nieland, Monty Krieger, Miao Yu
  • Patent number: 9944633
    Abstract: The invention relates to compounds of Formula I or a pharmaceutically acceptable salt, ester or prodrug thereof:
    Type: Grant
    Filed: August 4, 2015
    Date of Patent: April 17, 2018
    Assignees: The Broad Institute, Inc., PRESIDENT & FELLOWS OF HARVARD COLLEGE
    Inventors: Mahmud Hussain, Daisuke Ito, Jason Law, Matthias Leiendecker, Ke Liu, Benito Munoz, Stuart Schreiber, Alykhan Shamji, Andrew Stern
  • Patent number: 9944607
    Abstract: The present invention provides novel compounds (e.g., compounds of Formula (I)), and pharmaceutically acceptable salts, solvates, hydrate, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits comprising the inventive Compounds, or compositions thereof, for treating and/or preventing a fungal or protozoan infection, inhibiting the activity of a fungal or protozoan enzyme, killing a fungus or protozoan, or inhibiting the growth of a fungus or protozoan. The fungus may be a Candida species, Sacchawmyces species, or other pathogenic fungal species. The compounds of the invention may inhibit the activity of fungal or protozoan mitochondrial phosphate carrier protein.
    Type: Grant
    Filed: October 16, 2013
    Date of Patent: April 17, 2018
    Assignees: Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology, The Broad Institute, Inc.
    Inventors: Benjamin Vincent, Luke Whitesell, Susan L. Lindquist, Willmen Youngsaye, Stephen L. Buchwald, Jean-Baptiste Langlois, Jun Pu, Benito Munoz, Sivaraman Dandapani
  • Publication number: 20180099977
    Abstract: The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, wherein U, J, V, X, R2a, R2b, R2c, R5 and t are as described herein. The present invention relates generally to inhibitors of histone deacetylase and to methods of making and using them. These compounds are useful for promoting cognitive function and enhancing learning and memory formation. In addition, these compounds are useful for treating, alleviating, and/or preventing various conditions, including for example, neurological disorders, memory and cognitive function disorders/impairments, extinction learning disorders, fungal diseases and infections, inflammatory diseases, hematological diseases, and neoplastic diseases in humans and animals.
    Type: Application
    Filed: October 17, 2017
    Publication date: April 12, 2018
    Applicants: The Broad Institute, Inc., The General Hospital Corporation d/b/a Massachusetts General Hospital, Massachusetts Institute of Technology
    Inventors: Edward Holson, Florence Fevrier Wagner, Michel Weiwer, Li-Huei Tsai, Stephen J. Haggarty, Yan-Ling Zhang
  • Publication number: 20180072671
    Abstract: The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, wherein X1, X2, X3, X4, X5, W1, W2, W3, and W4 are as described herein. The present invention relates generally to inhibitors of histone deacetylase and to methods of making and using them. In one aspect, the invention relates to selective HDAC3 inhibitors useful for protecting ?-cells and improving insulin resistence. The selective HDAC3 inhibitors are also useful for promoting cognitive function and enhancing learning and memory formation.
    Type: Application
    Filed: August 16, 2017
    Publication date: March 15, 2018
    Applicants: The Broad Institute, Inc., The General Hospital Corporation d/b/a Massachusetts General Hospital
    Inventors: Edward Holson, Florence Fevrier Wagner, Stephen J. Haggarty, Yan-Ling Zhang, Morten Lundh, Bridget Wagner, Michael C. Lewis, Tracey Lynn Petryshen
  • Patent number: 9914717
    Abstract: The present invention provides compounds of formula (I) or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein W, X, n, s, t, and Ra are as described herein. The present invention relates generally to selective inhibitors of histone deacetylase and to methods of making and using them.
    Type: Grant
    Filed: December 19, 2013
    Date of Patent: March 13, 2018
    Assignee: The Broad Institute, Inc.
    Inventors: Edward Holson, Fanny Lazzaro, David Olson, Florence Fevrier Wagner, Michel Weiwer
  • Patent number: 9901631
    Abstract: The present invention provides genetically modified cells useful for viral replication and the production of viral vaccines.
    Type: Grant
    Filed: January 10, 2013
    Date of Patent: February 27, 2018
    Assignees: The Broad Institute, Inc., The General Hospital Corporation
    Inventors: Marciela Degrace, Nir Hacohen, Sagi Shapira, Liguo Wu
  • Patent number: 9890127
    Abstract: Disclosed are compounds, such as pyridazinones, that can be, inter alia, used for treating cancer.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: February 13, 2018
    Assignees: The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Timothy A. Lewis, Benito Munoz, Lucian De Waal, Heidi Greulich, Matthew Meyerson, Lara Nicole Gechijian
  • Patent number: 9890429
    Abstract: The present invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating cancer (e.g., hematological malignancies in humans). A variety of biomarker chromosomal number alterations (CNAs) and biomarkers corresponding thereto, are provided, wherein alterations in the copy number of one or more of the biomarker CNAs and/or alterations in the amount, structure, and/or activity of one or more of the biomarkers comprised within the CNAs is associated with cancer status.
    Type: Grant
    Filed: February 28, 2013
    Date of Patent: February 13, 2018
    Assignees: Dana-Farber Cancer Institute, Inc., The Broad Institute, Inc.
    Inventors: Margaret A. Shipp, Stefano Monti, Bjoern Chapuy, Scott J. Rodig, Todd R. Golub
  • Patent number: 9890172
    Abstract: The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, wherein U, J, V, X, R2a, R2b, R2c, R5 and t are as described herein. The present invention relates generally to inhibitors of histone deacetylase and to methods of making and using them. These compounds are useful for promoting cognitive function and enhancing learning and memory formation. In addition, these compounds are useful for treating, alleviating, and/or preventing various conditions, including for example, neurological disorders, memory and cognitive function disorders/impairments, extinction learning disorders, fungal diseases and infections, inflammatory diseases, hematological diseases, and neoplastic diseases in humans and animals.
    Type: Grant
    Filed: May 5, 2016
    Date of Patent: February 13, 2018
    Assignees: The Broad Institute, Inc., The General Hospital Corporation
    Inventors: Edward Holson, Florence Fevrier Wagner, Michel Weiwer, Stephen J. Haggarty, Yan-Ling Zhang